FIELD: chemistry.
SUBSTANCE: aminoaryl derivative represented by the chemical formula (1) and exhibiting the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor, a pharmaceutical composition containing it as an active ingredient. The invention relates to an aminoaryl derivative of the general formula (1) or a pharmaceutically acceptable salt or stereoisomer thereof, having inhibitory activity against diacylglycerol acyltransferase 2 (DGAT2). In this formula, each A and D is independently CH or N; each B and E is independently CH, C-halogen, C-halogen-C1-C7 alkyl, or N; R1 is C1-C7 alkyl; R2 is hydrogen or halogen; R3 is -G-J; where G represents C6-C10 aryl, C6-C10 arylene, C6-C10 arylene-C1-C7 alkylene, 5-12-membered heteroaryl or 5-12-membered heteroarylene; J is hydrogen, amino, aminocarbonyl, C1-C7 alkoxy-C1-C7 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkyloxy, 5-12 membered heterocycloalkyl, C6-C10 aryl, C6-C10 aryloxy, C6-C10 aryl-C1-C7 alkoxy, 5-12-membered heteroaryl, 5-12-membered heteroarylamino, carboxy-C1-C7 alkyl, carboxy-C2-C7 alkenyl, carboxy-C1-C7 alkyl-C6-C10 aryl, carboxy-C1-C7 alkoxy-C6-C10 aryl, carboxy-C1-C7 alkyl - 5-12-membered heterocycloalkyl, carboxy-C2-C7 alkenyl - 5-12-membered heterocycloalkyl, carboxy-C1-C7 alkoxy - 5-12-membered heterocycloalkyl, carboxy-C1-C7 alkylamino-C6-C10 aryl, carboxy-C1-C7 alkyl-C6-C10 aryloxy or carboxy-C1-C7 alkyl - 5-12-membered heteroaryl; where amino, alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl or heteroarylene is optionally substituted with 1-4 substituents selected from halogen, -COOH, C1-C7 alkyl, C1-C7 alkoxy, halogen-C1-C 7 alkyl, C1-C7 alkylsulfonyl and 5-12-membered heteroaryl-C1-C7 alkyl; and heterocycloalkyl, heteroaryl and heteroarylene contain 1-5 heteroatoms selected from N, O and S.
EFFECT: pharmaceutical composition for the treatment of diseases associated with diacylglycerol acyltransferase 2 (DGAT2) containing a compound of formula (1) or a pharmaceutically acceptable salt or stereoisomer as active ingredient together with a pharmaceutically acceptable carrier.
4 cl, 1 tbl, 180 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW AMIDE DERIVATIVE USED AS AN INHIBITOR OF DIALGLYCEROL O-ACYLTRANSFERASE 2 AND ITS USE | 2020 |
|
RU2810064C1 |
| NEW BIARYL DERIVATIVE USED AS INHIBITOR OF DIACYLGLYCEROL ACYLTRANSFERASE 2 AND ITS USE | 2021 |
|
RU2808433C1 |
| COMPOUND CONTAINING OXADIAZOLE AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | 2019 |
|
RU2789456C2 |
| NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITING ACTIVITY | 2019 |
|
RU2768755C1 |
| THIENO[3,2-d]PYRIMIDINE DERIVATIVES WITH PROTEIN KINASE INHIBITORY ACTIVITY | 2012 |
|
RU2705577C2 |
| AMINOPYRIMIDINE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2826628C1 |
| DIAMINOPYRIMIDINE DERIVATIVES AND METHODS FOR PRODUCTION THEREOF | 2012 |
|
RU2587981C2 |
| INDOLE COMPOUNDS AS CELL NECROSIS INHIBITORS | 2008 |
|
RU2477282C2 |
| BIARYL DERIVATIVE AS GPR120 AGONIST | 2015 |
|
RU2683648C2 |
| NEW COMPOUND, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2814103C1 |
